Refers to a compound derived from the amino acid - 2 - 1 - ciclopropiletilboronico of formula (i) where a is an integer between 0 and 2 p is H or a radical Block Group RA2 is C1 - C6 aliphatic Hydrogen, among others, fluoroalifatico C1 - C6 1 Z and Z2 are Hydroxy ariloxi, aralcoxi, alkoxy, or Form J Together a radical derived from Agent acomplejamiento boronico acid.Preferred compounds are: acid (cyclopropyl - (1R) - 2 - [1 - ((2S) - phenyl - 2 - (3 - ((4 - (2 - iloxi pyridin -) phenyl] sulfonyl] amino}} propanoil amino) ethyl) boronico acid, 2 - ((1R) - 2-cyclopropyl-1 - 1 - [(2S) - 2 - (6 - fenoxipiridin {[- 3 - il) sulfonyl] amino} - 3 - fenilpropanoil) amino] ethyl} boronico among others. In addition to such a Pharmaceutical composition.This Compound is a proteasome inhibitor used in the treatment of cancer.SE REFIERE A UN COMPUESTO DERIVADO DEL ACIDO 1-AMINO-2-CICLOPROPILETILBORONICO .DE FORMULA (I) DONDE: A ES UN ENTERO ENTRE 0 Y 2 P ES H O UN RADICAL DE BLOQUEO DE GRUPO Ra2 ES HIDROGENO, ALIFATICO C1-C6, FLUOROALIFATICO C1-C6 ENTRE OTROS Z 1 Y Z2 SON HIDROXI, ALCOXI, ARILOXI, ARALCOXI O FORMAN JUNTOS UN RADICAL DERIVADO DE AGENTE DE ACOMPLEJAMIENTO DE ACIDO BORONICO. SON COMPUESTOS PREFERIDOS: ACIDO((1R)-2-CICLOPROPIL-1-{[(2S)-3-FENIL-2-({[4-(PIRIDIN-2-ILOXI)FENIL]SULFONIL}AMINO)PROPANOIL]AMINO}ETIL)BORONICO, ACIDO{(1R)-2-CICLOPROPIL-1-[((2S)-2-{[(6-FENOXIPIRIDIN-3-IL)SULFONIL]AMINO}-3-FENILPROPANOIL)AMINO]ETIL}BORONICO ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE PROTEASOMA UTIL EN EL TRATAMIENTO DEL CANCER.
